| CAHR Abstracts 2002 |
CLINICAL SCIENCES / SCIENCES CLINIQUES
ORAL PRESENTATIONS / PRÉSENTATIONS ORALES
ART I: PHARMACOKINETICS, INTERACTIONS, AND PREDICTORS OF RESPONSE
[201] THE PHARMACOKINETICS OF SAQUINAVIR/RITONAVIR
400/400 mg BID BEFORE, AND AFTER SHORT- AND LONG-TERM CO-ADMINISTRATION OF EFAVIRENZ
600 mg QD
R van Heeswijk*, C Cooper, K Gallicano, G Carignan, Y Khaliq, I Seguin,
N Hawley, J Angel, AD Badley, G Garber, DW Cameron
University of Ottawa, Ottawa Health Research Institute, Ottawa Hospital General
Campus, Division of Infectious Diseases, Ottawa, Ontario
[202] EFFECT OF NONNUCLEOSIDES (NNRTIs) ON TROUGH
PLASMA LEVELS OF CONCOMITANT LOPINAVIR/ RITONAVIR (LPV/RTV) AND AMPRENAVIR (APV)
M Harris, C Alexander, L Ting, S Guillemi, J Mostyn, PR Harrigan, MV
O’Shaughnessy, JSG Montaner
BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia
[203] ADJUSTMENT OF METHADONE (MET) DOSES IN INTRAVENOUS
DRUG USERS (IDUs) INITIATING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)
Annabel Mead,1, Jennie Prasad2, Nadine Smith3,
Brian Conway1,2,3, Stanley de Vlaming1,2
1Pender Community Health Centre; 2Department of Pharmacology
and Therapeutics, University of British Columbia; 3Vancouver Coastal
Health Authority, Vancouver, British Columbia
[204] A SINGLE, UNTIMED DETERMINATION OF DRUG LEVELS
AFTER STARTING THERAPY IS A SIGNIFICANT PREDICTOR OF MORTALITY AFTER STARTING
ANTIRETROVIRAL THERAPY
Christopher S Alexander, Jérôme Asselin, RS Hogg, JSG Montaner, MV
O’Shaughnessy, P Richard Harrigan
BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia
[205] CLINICAL IMPLICATIONS OF POLYMORPHISMS WITHIN
THE HUMAN CX3CR1 CHEMOKINE RECEPTOR GENE IN HIV POSITIVE, ANTIRETROVIRAL NAIVE
INDIVIDUALS INITIATING THEIR FIRST THERAPY
WY Dong, ZL Brumme, KJ Chan, RS Hogg, JSG Montaner, MV O’Shaughnessy,
P Richard Harrigan
BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia
[206] CD4 AND VIRAL LOAD CHANGE PREDICT SUBSEQUENT
DISEASE PROGRESSION AMONG HIV-1 INFECTED PERSONS INITIATING ANTIRETROVIRAL THERAPY
RS Hogg, B Yip, K Chan, E Wood, R Harrigan, KJP Craib, MV O’Shaughnessy,
JSG Montaner
[207] THE EFFECT OF EARLY TREATMENT ON CHANGES
IN CD4+ CELL COUNT AMONG HIV-1 SEROCONVERTERS: RESULTS FROM THE POLARIS HIV
SEROCONVERSION STUDY
A Rachlis1,2, A Burchell3, K Logue1,4,
C Major5, K Gough1,6, S Read1,7, M Ostrowski1,6,
P Corey1, L Calzavara1,3, Polaris Study Team
1Faculty of Medicine, University of Toronto; 2Sunnybrook
and Women’s College Health Sciences Centre; 3HIV Social, Behavioural
and Epidemiological Studies Unit, University of Toronto; 4St Clair
Medical Association Research Institute; 5Ontario Ministry of Health
and Long Term Care; 6St Michael’s Hospital, Toronto; 7Hospital
for Sick Children, Toronto, Ontario
[208] PHYSICIAN EXPERIENCE IS AN
INDEPENDENT DETERMINANT OF HIV-RELATED MORTALITY AMONG PERSON INITIATING ANTIRETROVIRAL
THERAPY
R Hogg, E Wood, B Yip, MV O’Shaughnessy, JSG Montaner